AKAN Stock Overview
Through its subsidiaries, engages in the cultivation, manufacture, and distribution of cannabis-based products for medicinal use worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Akanda Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.75 |
| 52 Week High | US$28.40 |
| 52 Week Low | US$0.71 |
| Beta | 1.48 |
| 11 Month Change | -30.00% |
| 3 Month Change | -45.33% |
| 1 Year Change | -95.74% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.98% |
Recent News & Updates
Shareholder Returns
| AKAN | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -11.8% | -3.7% | -1.6% |
| 1Y | -95.7% | 17.2% | 30.8% |
Return vs Industry: AKAN underperformed the US Pharmaceuticals industry which returned 17.2% over the past year.
Return vs Market: AKAN underperformed the US Market which returned 30.8% over the past year.
Price Volatility
| AKAN volatility | |
|---|---|
| AKAN Average Weekly Movement | 10.0% |
| Pharmaceuticals Industry Average Movement | 9.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: AKAN's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: AKAN's weekly volatility has decreased from 22% to 10% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | n/a | Katie Field | www.akandacorp.com |
Akanda Corp., through its subsidiaries, engages in the cultivation, manufacture, and distribution of cannabis-based products for medicinal use worldwide. It offers medicinal-grade cannabis and cannabis based medical and wellness products. The company was incorporated in 2021 and is headquartered in New Romney, the United Kingdom.
Akanda Corp. Fundamentals Summary
| AKAN fundamental statistics | |
|---|---|
| Market cap | US$1.63m |
| Earnings (TTM) | -US$31.84m |
| Revenue (TTM) | US$2.51m |
0.6x
P/S Ratio-0.1x
P/E RatioIs AKAN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AKAN income statement (TTM) | |
|---|---|
| Revenue | US$2.51m |
| Cost of Revenue | US$2.25m |
| Gross Profit | US$259.56k |
| Other Expenses | US$32.10m |
| Earnings | -US$31.84m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -14.63 |
| Gross Margin | 10.35% |
| Net Profit Margin | -1,269.38% |
| Debt/Equity Ratio | 7.8% |
How did AKAN perform over the long term?
See historical performance and comparison